A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles

Jiang, Dongjie; Zhao, Na

doi:10.1007/s00432-006-0108-6

Cited by 10 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New affordable methods are therefore needed to help diagnosis and prognosis and to suggest the most appropriate treatment for patients with BC on an individual basis. As a solution, miRNAs have been proposed as promising biomarkers of BC because they can be readily detected in tumor biopsies (non-circulating miRNAs) 16 , 17 and are also stably found in body fluids (circulating miRNAs), particularly in blood, plasma, serum, and saliva 18 , 19 . These circulating miRNAs are highly reliable and protected from endogenous RNAse activity, being bound to lipoproteins such as HDL, associated with Argonaute 2 (Ago2) protein 20 , or packaged into microparticles (such as exosome-like particles, microvescicles, and apoptotic bodies.)…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer

Bertoli¹,

Cava²,

Castiglioni³

2015

Theranostics

714

498

View full text Add to dashboard Cite

Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of several human cancers, including breast cancer (BC), as strong evidence has been found that miRNAs can act as oncogenes or tumor suppressor genes. This review presents the state of the art on the role of miRNAs in the diagnosis, prognosis, and therapy of BC. Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335), and prediction of therapeutic outcomes (i.e., miR-30c, miR-187, and miR-339-5p) and have important roles in the control of BC hallmark functions such as invasion, metastasis, proliferation, resting death, apoptosis, and genomic instability. Other miRNAs are of interest as new, easily accessible, affordable, non-invasive tools for the personalized management of patients with BC because they are circulating in body fluids (e.g., miR-155 and miR-210). In particular, circulating multiple miRNA profiles are showing better diagnostic and prognostic performance as well as better sensitivity than individual miRNAs in BC. New miRNA-based drugs are also promising therapy for BC (e.g., miR-9, miR-21, miR34a, miR145, and miR150), and other miRNAs are showing a fundamental role in modulation of the response to other non-miRNA treatments, being able to increase their efficacy (e.g., miR-21, miR34a, miR195, miR200c, and miR203 in combination with chemotherapy).

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer

Bertoli¹,

Cava²,

Castiglioni³

2015

Theranostics

714

498

View full text Add to dashboard Cite

show abstract

“…Usually, based on sequence-specific binding, they can inhibit the translation of messenger RNA (mRNA) or mark mRNA molecules for degradation [89]. Due to molecular-technique improvement, new and affordable methods are available, suggesting that miRNAs can be used as promising biomarkers of MBs [90,91]. MiRNAs can be readily detected in tumor biopsies, and they are also stable in body fluids due to being bound to lipoproteins, associated with the Argonaute 2 (Ago2) protein, packaged into microvescicles and other microparticles (such as apoptotic bodies, microvesicles, and exosome-like particles) as circulating miRNAs [92][93][94].…”

Section: Non-coding Rnasmentioning

confidence: 99%

Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?

2023

View full text Add to dashboard Cite

Medulloblastomas, highly aggressive neoplasms of the central nervous system (CNS) that present significant heterogeneity in clinical presentation, disease course, and treatment outcomes, are common in childhood. Moreover, patients who survive may be diagnosed with subsequent malignancies during their life or could develop treatment-related medical conditions. Genetic and transcriptomic studies have classified MBs into four subgroups: wingless type (WNT), Sonic Hedgehog (SHH), Group 3, and Group 4, with distinct histological and molecular profiles. However, recent molecular findings resulted in the WHO updating their guidelines and stratifying medulloblastomas into further molecular subgroups, changing the clinical stratification and treatment management. In this review, we discuss most of the histological, clinical, and molecular prognostic factors, as well the feasibility of their application, for better characterization, prognostication, and treatment of medulloblastomas.

show abstract

“…Nevertheless, previous work has helped to define the clinicopathologic features of breast cancer, such as histological grade, lymph-node involvement, and status of hormone receptors, which have improved prognostic evaluation and guided therapeutic approaches for the disease [1,2]. The malignant transformation of tumor cells occurs via a multistep process that involves the reprogramming of pluripotency, which is considered the most challenging issue facing therapeutic intervention [3].…”

Section: Introductionmentioning

confidence: 99%

Increased Cellular Levels of MicroRNA-9 and MicroRNA-221 Correlate with Cancer Stemness and Predict Poor Outcome in Human Breast Cancer

Cheng

Hsieh

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background /Aims: Recent studies of microRNA (miRNA) involvement in tumorigenesis have indicated the critical role of these non-coding small RNAs in malignant transformation, but the prognostic role, if any, of miRNAs in breast cancer remains undetermined. Therefore, we assessed the prognostic significance of microRNA-9 (miR-9) and miR-221 in breast cancer toward the goal of understanding the contribution(s) of these miRNAs to cancer cell stemness. Methods: The level of each of miR-9 and miR-221 in 206 paired laser capture microdissected tumor cells and non-tumor cells was determined by quantitative reverse transcription-PCR (qRT-PCR). The relationship between the miRNA signature and clinicopathological data and prognosis of breast cancer was assessed. Identification of a stem cell-enriched side population was achieved with fluorescence-activated cell sorting and a sphere-forming assay. Wound healing, Boyden chamber assays, and western blotting were used to study the contribution of each miRNA to tumor cell migration and invasion. Results: We found that induction of miR-9 and miR-221 mimics conferred side-population cells to form spheroidal tumor colonies in suspension culture that maintained the mesenchymal stem-cell potential in non-invasive MCF-7 breast cancer cells. In contrast, knockdown of both miR-9 and miR-221 in invasive MDA-MB-231 breast cancer cells dramatically decreased the number of side-population colonies with stem cell-like potency, which reduced the capacity for tumor-cell renewal, invasion, and migration. Clinically, the mean proportion of miR-9- or miR-221-overexpressing cells was significantly greater in tumor cells compared with non-tumor cells (P < 0.05). Increased levels of miR-9 and miR-221 in breast tissue portended a significantly elevated risk of progression to malignancy with respect to larger tumor size, poor differentiation, late-stage evolution, lymph-node metastasis (P < 0.05), and lower overall survival (Ptrend = 0.017; eight-year follow-up). Conclusion: Our findings provide strong evidence that miR-9 and miR-221 can enhance the generation of cancer stem cells to yield an invasive phenotype and that overexpression of these miRNAs predicts a poor outcome for breast cancer patients.

show abstract

A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles

Abstract: Our predictive approach is useful in prognosis prediction for breast cancer patients with lymph node-negative. The gene markers provide valuable information for the progression of breast cancer and suggest potential target genes for treating the cancer.

Cited by 10 publications

References 34 publications

MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer

MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer

Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?

Increased Cellular Levels of MicroRNA-9 and MicroRNA-221 Correlate with Cancer Stemness and Predict Poor Outcome in Human Breast Cancer

Contact Info

Product

Resources

About